Journal ArticleDOI
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study
Shigeki Ohtake,Shuichi Miyawaki,Hiroyuki Fujita,Hitoshi Kiyoi,Katsuji Shinagawa,Noriko Usui,Hirokazu Okumura,Koichi Miyamura,Chiaki Nakaseko,Yasushi Miyazaki,Atsushi Fujieda,Tadashi Nagai,Takahisa Yamane,Masafumi Taniwaki,Masatomo Takahashi,Fumiharu Yagasaki,Yukihiko Kimura,Norio Asou,Hisashi Sakamaki,Hiroshi Handa,Sumihisa Honda,Kazunori Ohnishi,Tomoki Naoe,Ryuzo Ohno +23 more
TLDR
High-dose daunorubsicin and standard-dose idarubicin were equally effective for the treatment of adult acute myeloid leukemia, achieving a high rate of complete remission and good long-term efficacy.About:
This article is published in Blood.The article was published on 2011-02-24. It has received 214 citations till now. The article focuses on the topics: Idarubicin & Daunorubicin.read more
Citations
More filters
Journal ArticleDOI
An update of current treatments for adult acute myeloid leukemia
Hervé Dombret,C. Gardin +1 more
TL;DR: Progress has been made, notably in terms of standard drug dose intensification and safer allogeneic HSCT procedures, allowing a larger proportion of patients to achieve durable remission and improved identification of patients at relatively low risk of relapse should limit their undue exposure to the risks of HSCT in first remission.
Journal ArticleDOI
Cytarabine dose for acute myeloid leukemia.
Bob Löwenberg,Thomas Pabst,Edo Vellenga,Wim L.J. van Putten,Harry C. Schouten,Carlos Graux,Augustin Ferrant,Pieter Sonneveld,Bart J. Biemond,Alois Gratwohl,Georgine E. de Greef,Leo F. Verdonck,Martijn R. Schaafsma,Michael Gregor,Matthias Theobald,Urs Schanz,Johan Maertens,Gert J. Ossenkoppele +17 more
TL;DR: Induction therapy with cytarabine at the lower dose already produced maximal antileukemic effects for all response end points, suggesting a plateau in the dose-response relationship above this dose level.
Journal ArticleDOI
Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial
Alan Kenneth Burnett,Nigel H. Russell,Robert Kerrin Hills,Ann Hunter,Lars Kjeldsen,John Yin. Yin,Brenda Gibson,Keith Wheatley,Donald Milligan +8 more
TL;DR: FLAG-Ida is an effective remission induction treatment, with a high complete remission rate after course 1 and reduced relapse, and consolidation with MACE/MidAc is similar overall to high-dose cytarabine, but superior in high-risk patients.
Journal ArticleDOI
Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
Hubert Serve,Utz Krug,Ruth Wagner,M. Cristina Sauerland,Achim Heinecke,Uta Brunnberg,Markus Schaich,Oliver G. Ottmann,Justus Duyster,Hannes Wandt,Thomas Fischer,Aristoteles Giagounidis,Andreas Neubauer,Albrecht Reichle,Walter E. Aulitzky,Richard Noppeney,Igor Wolfgang Blau,Volker Kunzmann,Reingard Stuhlmann,Alwin Krämer,Karl-Anton Kreuzer,Christian Brandts,Björn Steffen,Christian Thiede,Carsten Müller-Tidow,Gerhard Ehninger,Wolfgang E. Berdel +26 more
TL;DR: Combination of standard induction and consolidation therapy with sorafenib in the schedule investigated in the trial is not beneficial for elderly patients with AML.
Journal ArticleDOI
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes
Utz Krug,Christoph Röllig,Anja Koschmieder,Achim Heinecke,Maria Cristina Sauerland,Markus Schaich,Christian Thiede,Michael S. Kramer,Jan Braess,Karsten Spiekermann,Torsten Haferlach,Claudia Haferlach,Steffen Koschmieder,Christian Rohde,Hubert Serve,Bernhard Wörmann,Wolfgang Hiddemann,Gerhard Ehninger,Wolfgang E. Berdel,Thomas Büchner,Carsten Müller-Tidow +20 more
TL;DR: The scores for acute myeloid leukaemia can be used to predict the probability of CR and the risk of ED in older patients with acuteMyeloid Leukaemia, but otherwise medically healthy, for whom intensive induction chemotherapy is planned.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Book ChapterDOI
Regression Models and Life-Tables
TL;DR: The analysis of censored failure times is considered in this paper, where the hazard function is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time.
Journal ArticleDOI
Asymptotically Efficient Rank Invariant Test Procedures
Richard Peto,Julian Peto +1 more
Journal ArticleDOI
The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial
David Grimwade,Helen Walker,Fiona Oliver,Keith Wheatley,Christine J. Harrison,G Harrison,J. K. H. Rees,Ian Hann,Richard L. Stevens,Alan Kenneth Burnett,Anthony H. Goldstone +10 more
TL;DR: Subgroup analysis demonstrated that the three cytogenetically defined prognostic groups retained their predictive value in the context of secondary as well as de novo AML, within the pediatric age group and furthermore were found to be a key determinant of outcome from autologous or allogeneic bone marrow transplantation (BMT) in first CR.
Journal ArticleDOI
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Bruce D. Cheson,John M. Bennett,Kenneth J. Kopecky,Thomas Büchner,Cheryl L. Willman,Elihu H. Estey,Charles A. Schiffer,Hartmut Doehner,Martin S. Tallman,T. Andrew Lister,Francesco Lo-Coco,Roel Willemze,Andrea Biondi,Wolfgang Hiddemann,Richard A. Larson,Bob Löwenberg,Miguel A. Sanz,David R. Head,Ryuzo Ohno,Clara D. Bloomfield +19 more
TL;DR: An International Working Group met to revise the diagnostic and response criteria for acute myelogenous leukemia originally published in 1990, as well as to provide definitions of outcomes and reporting standards to improve interpretability of data and comparisons among trials as mentioned in this paper.
Related Papers (5)
High-dose daunorubicin in older patients with acute myeloid leukemia.
Bob Löwenberg,Gert J. Ossenkoppele,Wim L.J. van Putten,Harry C. Schouten,Carlos Graux,Augustin Ferrant,Pieter Sonneveld,Johan Maertens,Mojca Jongen-Lavrencic,Marie von Lilienfeld-Toal,Bart J. Biemond,Edo Vellenga,Marinus van Marwijk Kooy,Leo F. Verdonck,Joachim Beck,Hartmut Döhner,Alois Gratwohl,Thomas Pabst,Gregor Verhoef +18 more
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
Hartmut Döhner,Elihu H. Estey,Sergio Amadori,Frederick R. Appelbaum,Thomas Büchner,Alan Kenneth Burnett,Hervé Dombret,Pierre Fenaux,David Grimwade,Richard A. Larson,Francesco Lo-Coco,Tomoki Naoe,Dietger Niederwieser,Gert J. Ossenkoppele,Miguel A. Sanz,Jorge Sierra,Martin S. Tallman,Bob Löwenberg,Clara D. Bloomfield +18 more